SARS-COV-2 Vaccination Response in Non-Domestic Species Housed at the Toronto Zoo

<b>Background</b>: Due to the wide host range of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination has been recommended for susceptible species in zoological collections, particularly to protect endangered species. The Zoetis^® Experimental Mink Coronavirus Vaccine (Subunit) was temporarily authorized in 2021-2024 for emergency use in North America for this purpose. However, there are limited data regarding its safety or efficacy in non-domestic mammals. The present study was conducted to assess the ability of this vaccine to elicit serum neutralizing titers against SARS-CoV-2 in selected animals from the Toronto Zoo (TZ) vaccinated during 2022. <b>Methods</b>: Serum samples were collected from 24 individuals across four families (<i>Cervidae</i>, <i>Felidae</i>, <i>Ursidae</i>, and <i>Hyaenidae</i>) and tested using a surrogate virus neutralization test (sVNT) and a plaque-reduction neutralization test (PRNT). <b>Results:</b> The results showed that all species developed some neutralizing titers after at least one vaccine dose, except for polar bears, which showed no seroconversion. Felids and hyenas had the highest neutralizing titers, which peaked at 3 and declined between 4 and 6 months after boost. These differences may stem from species-specific immune responses or lack of vaccination protocols tailored to individual species. <b>Conclusions</b>: While natural infection with SARS-CoV-2 could not be ruled out in the cohort of this study, insights from our results have the potential to inform future vaccine recommendations for non-domestic species. Furthermore, our study highlighted the value of competitive assays in assessing serological responses across a broad range of exotic species, for which reagents, such as anti-isotype antibodies, are often unavailable.